Strong Travis D, Gebska Milena A, Burnett Arthur L, Champion Hunter C, Bivalacqua Trinity J
Department of Urology, Johns Hopkins Hospital, Baltimore, MD 21287, USA.
Asian J Androl. 2008 Jan;10(1):14-22. doi: 10.1111/j.1745-7262.2008.00362.x.
Erectile dysfunction (ED) commonly results from endothelial dysfunction of the systemic vasculature. Although phosphodiesterase type 5 (PDE-5) inhibitors are effective at treating most cases of ED, they must be taken routinely and are ineffectual for a meaningful number of men. In recent years gene and stem cell-based therapies targeted at the penile endothelium have been gaining momentum in preclinical studies. These early studies reveal that gene and stem cell-based therapies may be both enduring and efficacious, and may eventually lead to a cure for ED. The following review will highlight our current understanding of endothelial-specific gene and stem cell-based therapies performed to date in a number of experimental animal models.
勃起功能障碍（ED）通常由全身血管系统的内皮功能障碍引起。尽管5型磷酸二酯酶（PDE-5）抑制剂对大多数ED病例有效，但必须常规服用，且对相当数量的男性无效。近年来，针对阴茎内皮的基因和干细胞疗法在临床前研究中越来越受到关注。这些早期研究表明，基因和干细胞疗法可能既持久又有效，最终可能治愈ED。以下综述将重点介绍我们目前对迄今为止在多种实验动物模型中进行的内皮特异性基因和干细胞疗法的理解。
